

Special Issue

The Development of Recombinant and Subunit Vaccines Against Infectious Diseases

Message from the Guest Editor

While significant progress has been made in preventing and controlling infectious diseases globally, humanity continues to suffer from their devastating effects. Vaccines play a crucial role in combating infectious diseases. Many successful vaccines have been developed to immunize against human infectious diseases, thereby reducing morbidity and mortality. One strategy for developing new and more effective vaccines involves using immunogenic proteins in the form of recombinant vaccines. However, recombinant proteins are generally weak antigens and necessitate appropriate adjuvants and delivery systems to enhance their protective efficacy. Incorporating adjuvants can reduce the antigens required to elicit an optimal immune response, thereby minimizing adverse effects at the inoculation site. This Special Issue invites original research and review articles on the efficacy of adjuvanted recombinant vaccines in preclinical and clinical trials against bacterial, parasitic, fungal, and viral infections for consideration.

Guest Editor

Prof. Dr. Abu Salim Mustafa
Department of Microbiology, College of Medicine, Health Sciences
Centre, Kuwait University, Kuwait City, Kuwait

Deadline for manuscript submissions

closed (31 October 2025)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/209831

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).